Oversubscribed seed round for Ecublens biotech startup
Summary
Resulting from over ten years of research in microfluidic and stem-cell engineering, HemostOD has developed a unique bioreactor that enables the manufacturing of ex-vivo platelets in just a few hours. The startup’s technology provides a revolutionary alternative to today’s blood donor platelets system with reliable access and long-run cost-effectiveness. The proceeds will support progression towards clinical stages, which will also lead to the scale-up of the technology, the development of an unlimited source of platelet mother cells and the consolidation of the manufacturing process and pre-clinical package in accordance with regulatory authorities. With 30 years of experience in the pharmaceutical industry, his contribution will be key for developing HemostOD’s product, future market launch and overall success. This financing round is an important step towards achieving the next company milestones as planned by the HemostOD team,” commented Massuyeau.